Skip to main content
Erschienen in: BMC Cancer 1/2010

Open Access 01.12.2010 | Research article

Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes

verfasst von: Vibeke Andersen, Jane Christensen, Kim Overvad, Anne Tjønneland, Ulla Vogel

Erschienen in: BMC Cancer | Ausgabe 1/2010

Abstract

Background

Transcription factors and nuclear receptors constitute a link between exposure to heterocyclic amines and polycyclic aromatic hydrocarbons from meat and tobacco smoke and colorectal cancer (CRC) risk. The aim of this study was to investigate if polymorphisms in nuclear factor kappa-B, pregnane X receptor, and liver X receptor were associated with risk of CRC, and to investigate possible interactions with lifestyle factors such as smoking, meat consumption, and NSAID use.

Methods

The polymorphisms nuclear factor kappa-B (NFkB, NFKB1) -94 insertion/deletion ATTG (rs28362491), pregnane X receptor (PXR, NR1I2) A-24381C (rs1523127), C8055T (rs2276707), A7635G (rs6785049), liver X receptor (LXR-β, NR1H3) C-rs1405655T, T-rs2695121C were assessed together with lifestyle factors in a nested case-cohort study of 378 CRC cases and 756 random participants from the Danish prospective Diet, Cancer and Health study of 57,053 persons.

Results

Carriers of NFkB -94deletion were at 1.45-fold higher risk of CRC than homozygous carriers of the insertion allele (incidence rate ratio (IRR) = 1.45, 95% confidence interval (95% CI): 1.10-1.92). There was interaction between this polymorphism and intake of red and processed meat in relation to CRC risk. Carriers of NFkB -94deletion were at 3% increased risk pr 25 gram meat per day (95% CI: 0.98-1.09) whereas homozygous carriers of the insertion were not at increased risk (p for interaction = 0.03). PXR and LXR polymorphisms were not associated with CRC risk. There was no interaction between use of nonsteroid antiinflammatory drugs (NSAID) or smoking status and NFkB, PXR or LXR polymorphisms.

Conclusions

A polymorphism in NFkB was associated with CRC risk and there was interaction between this polymorphism and meat intake in relation to CRC risk. This study suggests a role for NFkB in CRC aetiology.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1471-2407-10-484) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

UV carried out the molecular genetic studies. UV, KO, AT participated in the design of the study and JC performed the statistical analysis. VA conceived the study and drafted the manuscript. All authors read and approved the final manuscript.
Abkürzungen
ABCB2
ATP-binding cassette (ABC) transporter B2 (MDR1)
ABCC2
ATP-binding cassette (ABC) transporter C2 (MRP2)
ABCG2
ATP-binding cassette (ABC) transporter B2 (BCRP)
COX-2
cyclooxygenase-2
CRC
colorectal cancer
IL-1β
interleukin 1-β
LXR
Liver X receptor (NR1H3)
MMP-9
matrix metalloproteinase-9
LPS
lipopolysaccharide
NSAID
non-steroidal anti-inflammatory drugs
NFkB
nuclear factor kappa-B (NFKB1)
PXR
pregnane X receptor (NR1I2)
SNP
single nucleotide polymorphism
TNF-α
tumor nekrosis factor-α
VEGF
vascular endothelial growth factor

Background

Colorectal cancer (CRC) constitutes the second most common cause of all cancer-related incidence and mortality in the Western World [1]. Risk factors include diet, lifestyle factors and genetic predisposition and as much as 50% of the CRC etiology has been attributed to diet [1, 2]. Intake of red and processed meat is a risk factor for CRC and Danes have the highest meat intake per capita in the World [1, 3, 4]. The exact mechanisms by which intake of meat and processed meat promotes carcinogenesis is not clear [5]. Red and processed meat represent sources of carcinogenic heterocyclic amines (HCA), polycyclic aromatic hydrocarbons (PAH) as well as N-nitroso compounds caused by cooking at high temperature and by processing of meat [5]. Moreover, heme in meat may cause oxidative stress, oxidative DNA damage and carcinogenesis [6]. Tobacco smoking has also been reported to confer risk of CRC [7, 8] and Danes have a high prevalence of smokers [9, 10]. Tobacco contains a large number of mutagenic and carcinogenic compounds, including PAH, nitrosamines, and nicotine [11]. PAHs and other carcinogens from tobacco smoke may reach the intestinal lumen after swallowing of inhaled particles and smoke carcinogens may then be taken up the same way as meat carcinogens. Long term use of aspirin and other non-steroidal anti-inflammatory drugs (NSAID) has been found to confer protection against CRC [12, 13]. Important mechanisms may be induction of apoptosis in CRC cells by a NFkB dependent pathway as well as suppression of inflammation [14, 15].
Gene-environment interaction studies have provided novel insights into the pathogenesis of CRC [1619]. We have recently found interaction between meat intake and polymorphisms in the ATP-binding cassette (ABC) transporter B1 (ABCB1, MDR1) which encodes glycoprotein P involved in reverse transport of carcinogens and other xenobiotic substances [20]. The expression of human MDR1 is regulated by pregnane X receptor (PXR) and nuclear factor-κB (NFkB) [21] whereas other xenobiotic transporters such as ABCC2 (MRP2) seem to be regulated by PXR and Liver X receptor (LXR) and ABCG2 (BCRP) by Peroxisome Proliferator-Activated Receptor γ (PPARγ) [2124].
In relation to cancer development, the most important effects of NFkB activation by tobacco smoke, PAH and bacterial components is considered to be inhibition of cell apoptosis caused by the increased transcription of genes such as interleukin 1-β (IL-1β) and cyclooxygenase-2 (COX-2) [25, 26]. Such a role for NFkB in tumor promotion is supported by the lower tumor incidence and size of tumors after inactivation of NFkB in animal studies [27]. On the other hand, functional NFkB seem to be required to control inflammation [28, 29] and IL-1β expression [30] and to induce apoptosis [15]. A functional ATTG insertion/deletion (ins/del) polymorphism in the promoter region of NFkB gene was associated with lower transcription levels of the del-allele in luciferase reporter systems [31] and risk of CRC in a Swedish, but not in a Chinese study population [32].
Activation of PXR by xenobiotica, including carcinogens, leads to up-regulation of enzymes and transporters involved in carcinogen handling including MDR1 [33] and to repression of NFkB and other pro-carcinogenic genes [34]. Persons homozygous for the PXR A7635G (rs2276707) G-allele and persons carrying at least one PXR C8055T (rs6785049) T-allele have significant higher levels of intestinal CYP3A level following in vivo treatment with the inducer rifampin than the homozygous wildtype carriers [35]. Activation of LXR by fatty acids, bacteria and cytokines leads to repression of pro-carcinogenic genes as IL-1β, COX-2, MMP-9 and NFkB [36]. The LXR-β marker polymorphisms rs1405655 and rs2695121 have been investigated as risk genes for Alzheimers disease with negative results [37].
We hypothesized that carriers of the NFκB -94del allele and PXR A7635G A-allele and C8055T C-allele would be at higher risk of CRC, especially among smokers and with high intake of red meat, whereas a protective effect of nonsteroid antiinflammatory drugs (NSAID) use was expected. We investigated the association between polymorphisms in NFkB (NFkB1) -94 insertion/deletion ATTG (rs28362491), PXR (NR1I2) A-rs1523127-C, C-rs2276707-T, A-rs6785049-G, LXR (NR1H2) C-rs1405655-T, T-rs2695121-C and risk of CRC, as well as interactions between genes and consumption of red and processed meat, smoking status and use of NSAID in relation to the development of CRC, in a case-cohort study nested in the prospective population-based Danish Diet, Cancer and Health study.

Methods

Studied Subjects

The subjects were selected from the Danish Diet, Cancer and Health study, an ongoing prospective cohort study [38]. Between December 1993 and May 1997, 160,725 individuals aged 50 to 64 years, born in Denmark, living in the Copenhagen and Aarhus areas and having no previous cancers at the time of invitation, were invited to participate in the study. A total of 57,053 persons accepted the invitation.
The colorectal cancer study group has been described previously [17, 19, 20, 39, 40].
In total, 405 cases (184 women and 221 men) of colorectal cancer were diagnosed among the cohort members between 1994 and 2003 and registered in the files of the nationwide Danish Cancer Registry [19]. Within the cohort we defined a sub-cohort sample including 368 women and 442 men who were randomly selected. Cases and the sub-cohort sample were frequency-matched on gender. Blood samples were available for 397 cases and 800 sub-cohort members. The numbers of unknown genotypes were 16 and 37 and the numbers of unavailable food frequency questionnaire were 11 and 17, among cases and sub-cohort members, respectively. All information on genotypes and lifestyle factors was available for 378 cases and 756 sub-cohort members who were included in the statistical analyses. A flow chart is shown in Figure 1.

Lifestyle variables

At enrolment, detailed information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected [38]. In the food-frequency questionnaire, meat consumption was assessed in 12 categories of predefined responses, ranking from 'never' to 'eight times or more per day'. The daily intake was then calculated by using FoodCalc [41], a program which uses population specific standardized recipes and portion sizes. Intake of red meat in grams per day was calculated by adding up intake of beef, veal, pork, lamb and offal. Intake of processed meat in grams per day was calculated by adding up intake of processed red meat, including bacon, smoked ham, salami, frankfurter, Cumberland sausage, cold cuts and liver pâté. Total dietary fibers are calculated by the AOAC methods [42]. Pearson correlation coefficients (adjusted for total energy intake) illustrating the comparison of nutrient scores estimated from the food-frequency questionnaire and from the diet records were 0.39 and 0.53 for dietary fibers, 0.56 and 0.48 for iron, and 0.37 and 0.14 for meat for men and women, respectively [43, 44].
Smoking status was categorized in three categories, never smoker, past smoker and current smoker based on the questionnaire.
The lifestyle questionnaire included questions regarding use of specific types of NSAID [45]. Based on all records, we classified study subjects according to use of "any NSAID" (≥ 2 pills per month during one year) at baseline.
Data on hormone replacement therapy (HRT), alcohol intake and anthropometric measurements, and physical activity was obtained from the questionnaire as previously described [38]. The body mass index (BMI) was calculated as weight (kg) per height (m) squared.

Blood sampling and storage

Blood was collected at enrolment and prepared as previously described [46]. In short, a total of 30 ml blood was collected in citrated (2 × 10 ml) and plain (1 × 10 ml) Venojects from each non-fasting participant, and lymphocytes were isolated and frozen at -20°C within 2 hours. At the end of the day of collection, all samples were stored in liquid nitrogen, at -150 ˚C.

Genotyping

DNA was isolated from frozen lymphocytes as described [47]. Generally, 100 μg DNA were obtained from 107 lymphocytes.
Genotypes were determined by Taqman allelic discrimination (ABI 7500/7900HT, Applied Biosystems). Twenty ng of DNA was analysed in 4 μl volumes. Cases and sub-cohort members were mixed during genotyping and laboratory staff was blinded to case/control status during analysis. Triplicates of genotype controls of all three genotypes were included in each run. The controls were selected in pilot genotype determinations of DNA from the same cohort. Ten % of the samples were randomly selected and genotyped again for reproducibility with 100% identity.
NFKB1 ATTG ins/del (rs28362491) was determined as described [48]. Four μl reactions contained ca. 20 ng DNA, 2 μl mastermix (Applied Biosystems, Birkerød, Denmark), 100 nM of each probe and 900 nM primers. Primer sequences were: F: 5'-CTA TGG ACC GCA TGA CTC TAT CAG-3' R: 5'-GGG CTC TGG CTT CCT AGC A-3'. Probe sequences were: NFKB -INS: 5'-FAM-ACC ATT GAT TGG GCC CGG-BHQ-3', NFKB-del: 5'-Yakima Yellow-CCG ACC ATT GGG CCC G-BHQ-3'.
PXR (NR1I2) A-24381C (rs1523127), C8055T (rs2276707), A7635G (rs6785049), LXR-β (NR1H3) C-rs1405655T, and T-rs2695121C were assayed using pre-developed assays (Applied Biosystems).

Statistical Analysis

The analyses were performed according to the principles for the analysis of case-cohort studies as described by Barlow [49]. The analyses were performed unweighted. Age was used as the time scale in the Cox regression model. Tests and confidence intervals were based on Wald's test using the robust estimate of the variance-covariance matrix for the regression parameters in the Cox regression model [50].
All models were adjusted for baseline values of established risk factors for colorectal cancer such as BMI (kg/m2, continuous), NSAID (yes/no), use of HRT (never/past/current, among women), smoking status (never/past/current), and intake of dietary fibers (g/day, continuous), red meat (g/day, continuous), alcohol intake (g/day, continuous), and physical activity (hours/day, continuous).
We investigated possible interactions between the genes and selected environmental factors using the likelihood ratio test. Tertiles of meat intake was defined as bounderies of intake of red and processed meat among the case group when devided into tertiles. Trend test were calculated using the Wald test. The procedure PHREG in SAS (release 9.1; SAS Institute Inc., Cary, NC, USA) was used for the statistical analyses.

Ethics

All participants gave verbal and written informed consent. Diet, Cancer and Health and the present sub-study were approved by the regional Ethics Committees on Human Studies in Copenhagen and Aarhus (Jr.nr. (KF)11-037/01 and jr.nr. (KF)01-045/93), and by the Danish Data Protection Agency.

Results

Characteristics of the study population and risk factors for CRC are shown in Table 1. The genotype distributions among the participants in the sub-cohort sample did not deviate from Hardy-Weinberg equilibrium (results not shown).
Table 1
Baseline characteristics of study participants selected from the Danish Diet, Cancer and Health prospective cohort study.
 
Cases
Sub-cohort
 
No. (%)
Median (5-95%)
No. (%)
Median (5-95%)
Total
378 (100)
 
756 (100)
 
Gender
    
   Men
207 (55)
 
409 (54)
 
   Women
171 (45)
 
347 (46)
 
Age at inclusion
 
58 (51-64)
 
56 (50-64)
Topology
    
   Proximal segment of colon
42 (11)
   
   Distal segment of colon
148 (39)
   
   Rectal
136 (36)
   
   Not specified
52 (14)
   
BMI
 
26 (21-34)
 
26 (21-33)
Food intake
    
   Alcohol, g/day
 
14 (1-69)
 
13 (1-61)
   Red meat, g/day
 
82 (37-171)
 
82 (32-177)
   Processed meat, g/day
 
26 (6-79)
 
25 (4-76)
   Dietary fibres g/day
 
20 (10-32)
 
21 (11-34)
Smoking status at inclusion
    
   Never
116 (31)
 
250 (33)
 
   Former
113 (30)
 
238 (31)
 
   Present
149 (39)
 
268 (35)
 
NSAID use
    
   No
123 (33)
 
234 (31)
 
   Yes
255 (67)
 
522 (69)
 
HRT use among women
    
   Never
100 (58)
 
186 (54)
 
   Former
26 (15)
 
58 (17)
 
   Present
45 (26)
 
103 (30)
 
Observed median values (5-95 percentiles) or percents of the distribution of baseline characteristics among cases and members of the comparison group.
Carriers of the NFkB -94del were at 1.45-fold (95% confidence interval (CI): 1.10-1.92) higher risk of CRC than homozygous carriers of the ins allele (Table 2) whereas PXR and LXR genotypes were not associated with CRC risk (Table 2). Haplotype analyses of the PXR gene showed eight different haplotypes. The most frequent haplotypes were the A-rs1523127-C/A- rs6785049-G/C-rs2276707-T combinations showing CGC, AAC, and the AGC which had frequencies of 0.12, 0.40 and 0.14, respectively. Haplotype analyses of the LXR gene showed four different haplotypes. The frequencies were for the C-rs1405655-T/T-rs2695121-C combinations TC, TT, CT and CC 0.33, 0.30, 0.24, and 0.12, respectively. No association was found between any of the eight PXR or four LXR haplotypes and CRC (data not shown).
Table 2
Incidence rate ratios (IRR) for colorectal cancer for the studied gene polymorphisms.
 
Ncases
Nsub-cohort
IRRA
95% CI
IRRB
95% CI
p-valueC
NFkB -94ins/del
       
   II
121
307
1.00
-
1.00
-
0.03
   ID
195
347
1.46
(1.10-1.93)
1.44
(1.07-1.92)
 
   DD
62
102
1.50
(1.02-2.22)
1.50
(1.00-2.25)
 
   ID and DD
257
449
1.47
(1.12-1.92)
1.45
(1.10-1.92)
 
PXR rs1523127
       
   AA
127
257
1.00
-
1.00
-
0.78
   AC
188
371
0.99
(0.74-1.31)
0.99
(0.74-1.32)
 
   CC
63
128
1.08
(0.74-1.57)
1.12
(0.77-1.65)
 
   AC and CC
251
499
1.01
(0.77-1.32)
1.02
(0.77-1.34)
 
PXR rs2276707
       
   CC
237
441
1.00
-
1.00
-
0.66
   CT
122
270
0.87
(0.67-1.14)
0.88
(0.67-1.17)
 
   TT
19
45
0.83
(0.46-1.49)
0.89
(0.49-1.62)
 
   CT and TT
141
315
0.87
(0.67-1.12)
0.88
(0.68-1.15)
 
PXR rs6785049
       
   AA
136
259
1.00
-
1.00
-
0.60
   AG
187
398
0.91
(0.69-1.21)
0.90
(0.67-1.21)
 
   GG
55
99
1.10
(0.74-1.64)
1.09
(0.72-1.65)
 
   AG and GG
242
497
0.95
(0.73-1.24)
0.94
(0.71-1.24)
 
LXR rs1405655
       
   CC
169
347
1.00
-
1.00
-
0.88
   CT
169
335
1.00
(0.77-1.31)
1.00
(0.76-1.31)
 
   TT
40
74
1.05
(0.68-1.63)
1.12
(0.71-1.76)
 
   CT and TT
209
409
1.01
(0.79-1.31)
1.02
(0.79-1.32)
 
LXR rs2695121
       
   TT
117
221
1.00
-
1.00
-
0.36
   CT
187
368
0.93
(0.69-1.25)
0.91
(0.67-1.23)
 
   CC
74
167
0.78
(0.54-1.12)
0.77
(0.53-1.11)
 
   CT and CC
261
535
0.88
(0.67-1.17)
0.86
(0.65-1.15)
 
ACrude (adjusted for age and sex).
BAdditionally adjusted for status of HRT (women only), smoking status, alcohol, dietary fibre, red meat, physical activity and BMI and NSAID use.
Cp-value for trend for the adjusted estimates.
Since we observed no allele-dose effects, all variant allele carriers were combined in subsequent analyses to maximize the statistical power. Del-allele carriers of NFkB -94ins/del were at 3% higher risk pr 25 g meat/day (CI: 0.98-1.09) whereas among homozygous carriers of the ins-allele, the association was in the opposite direction (IRR pr 25 g/day: 0.97, CI: 0.90-1.04, p for interaction= 0.03) (Table 3). Table 4 shows the IRRs for tertiles of intake of red and processed meat subdivided by the NFkB genotypes. Among homozygous ins-allele carriers of the NFkB -94ins/del polymorphism, IRRs were unchanged across tertiles of meat intake, whereas for del-allele carriers, the risk of CRC was higher for the second and the third tertile of meat intake compared to the first tertile (Table 4). In this analysis, there was no statistical significant interaction.
Table 3
Incidence rate ratios (IRR) for colorectal cancer per additional intake of 25 g red or processed meat subdivided by the studied genotypes.
   
Red and processed meat
 
Ncases
Nsub-cohort
IRRA
95% CI
IRRB
95% CI
p-valueC
NFkB -94ins/del
       
   II
121
307
0.96
(0.90-1.03)
0.97
(0.90-1.04)
0.03
   ID and DD
257
449
1.03
(0.98-1.08)
1.03
(0.98-1.09)
 
PXR rs1523127
       
   AA
127
257
1.04
(0.98-1.12)
1.04
(0.97-1.12)
0.28
   AC and CC
251
499
1.01
(0.96-1.06)
1.01
(0.96-1.07)
 
PXR rs2276707
       
   CC
237
441
1.02
(0.97-1.08)
1.02
(0.97-1.08)
0.53
   CT and TT
141
315
1.01
(0.95-1.07)
1.01
(0.94-1.08)
 
PXR rs6785049
       
   AA
136
259
1.01
(0.95-1.07)
1.01
(0.95-1.08)
0.72
   AG and GG
242
497
1.02
(0.97-1.08)
1.02
(0.97-1.08)
 
LXR rs1405655
       
   CC
169
347
1.02
(0.97-1.07)
1.02
(0.96-1.08)
0.91
   CT and TT
209
409
1.02
(0.96-1.08)
1.02
(0.96-1.08)
 
LXR rs2695121
       
   TT
117
221
1.04
(0.98-1.12)
1.05
(0.97-1.12)
0.28
   CT and CC
261
535
1.01
(0.96-1.07)
1.01
(0.96-1.07)
 
ACrude (adjusted for age and sex).
BAdditionally adjusted for status of HRT (women only), smoking status, alcohol, dietary fibre, physical activity, NSAID use and BMI.
Cp-value for interaction between genotype and red and processed meat for the adjusted estimates.
Table 4
Incidence rate ratios (IRR) for colorectal cancer for tertiles of intake of red and processed meat subdivided by the NFkB genotypes.
 
Red and processed meat
IRRA95% CI
p-valueB
 
1. tertile
2. tertile
3. tertile
Red and processed meat
 
 
N C
N S
N C
N S
N C
N S
<91.4 g/day
91.4-130.2 g/day
>130.2 g/day
 
NFkB -94ins/del
             
   II
46
107
35
98
40
102
1.00
-
0.88
(0.50-1.54)
1.07
(0.61-1.88)
0.16
   ID and DD
78
157
91
137
88
155
1.19
(0.75-1.91)
1.70
(1.06-2.74)
1.44
(0.89-2.34)
 
AAdjusted for status of HRT (women only), smoking status, alcohol, dietary fibre, BMI, physical activity and NSAID use.
Bp-value for interaction.
No interactions between smoking status or NSAID use and the studied genotypes were found (Tables 5 and 6).
Table 5
Interaction between the studied polymorphisms and smoking status.
 
Smoking
IRRA95% CI
p-valueB
 
Never
Past
Current
Smoking
 
 
NC
NS
NC
NS
NC
NS
Never
Past
Current
 
NFkB -94ins/del
             
   II
37
101
37
101
47
105
1.00
-
0.89
(0.51-1.55)
1.15
(0.67-1.97)
0.84
   ID and DD
79
149
76
137
102
163
1.45
(0.89-2.37)
1.41
(0.86-2.33)
1.55
(0.96-2.51)
 
PXR rs1523127
             
   AA
33
94
42
76
52
87
1.00
-
1.37
(0.77-2.47)
1.55
(0.89-2.70)
0.08
   AC and CC
83
156
71
162
97
181
1.49
(0.90-2.45)
1.15
(0.69-1.91)
1.38
(0.84-2.28)
 
PXR rs2276707
             
   CC
63
141
70
135
104
165
1.00
-
1.01
(0.65-1.57)
1.24
(0.82-1.87)
0.43
   CT and TT
53
109
43
103
45
103
1.06
(0.66-1.68)
0.89
(0.54-1.47)
0.93
(0.57-1.51)
 
PXR rs6785049
             
   AA
40
89
38
85
58
85
1.00
-
0.92
(0.52-1.61)
1.37
(0.80-2.33)
0.28
   AG and GG
76
161
75
153
91
183
1.06
(0.65-1.72)
1.00
(0.61-1.63)
1.04
(0.64-1.67)
 
LXR rs1405655
             
   CC
49
117
54
116
66
114
1.00
-
0.93
(0.56-1.54)
1.18
(0.72-1.92)
0.83
   CT and TT
67
133
59
122
83
154
1.07
(0.66-1.72)
1.01
(0.62-1.64)
1.11
(0.71-1.74)
 
LXR rs2695121
             
   TT
36
74
35
63
46
84
1.00
-
1.12
(0.61-2.07)
1.20
(0.67-2.13)
0.67
   CT and CC
80
176
78
175
103
184
0.98
(0.59-1.63)
0.85
(0.51-1.42)
1.03
(0.63-1.70)
 
AAdjusted for age, sex, status of hormone replacement therapy (HRT)(women only), alcohol, dietary fibre and BMI, physical activity and NSAID use.
B P-value for interaction.
Table 6
Interaction between gene polymorphisms and NSAID use.
 
NSAID
IRRA95% CI
IRRB95% CI
p-valueC
 
NO
YES
NSAID
NSAID
 
 
N C
NS
NC
NS
NO
YES
NO
YES
 
NFkB -94ins/del
             
   II
83
210
38
97
1.00
-
1.09
(0.69-1.73)
1.00
-
1.03
(0.64-1.65)
0.82
   ID and DD
172
312
85
137
1.47
(1.06-2.03)
1.60
(1.09-2.35)
1.43
(1.02-1.99)
1.55
(1.04-2.31)
 
PXR rs1523127
             
   AA
83
172
44
85
1.00
-
1.09
(0.69-1.73)
1.00
-
1.07
(0.67-1.71)
0.99
   AC and CC
172
350
79
149
1.01
(0.73-1.40)
1.11
(0.75-1.63)
1.02
(0.73-1.43)
1.09
(0.73-1.63)
 
PXR rs2276707
             
   CC
161
296
76
145
1.00
-
1.01
(0.72-1.43)
1.00
-
0.96
(0.67-1.37)
0.25
   CT and TT
94
226
47
89
0.81
(0.59-1.12)
1.01
(0.67-1.53)
0.81
(0.59-1.12)
1.02
(0.66-1.56)
 
PXR rs6785049
             
   AA
90
180
46
79
1.00
-
1.11
(0.70-1.74)
1.00
-
1.07
(0.67-1.71)
0.98
   AG and GG
165
342
77
155
0.96
(0.69-1.32)
1.04
(0.71-1.53)
0.94
(0.67-1.32)
1.00
(0.67-1.49)
 
LXR rs1405655
             
   CC
117
238
52
109
1.00
-
1.00
(0.67-1.50)
1.00
-
0.94
(0.62-1.44)
0.32
   CT and TT
138
284
71
125
0.96
(0.71-1.31)
1.13
(0.78-1.65)
0.95
(0.69-1.30)
1.12
(0.76-1.64)
 
LXR rs2695121
             
   TT
85
161
32
60
1.00
-
1.08
(0.64-1.80)
1.00
-
1.02
(0.58-1.78)
0.75
   CT and CC
170
361
91
174
0.87
(0.62-1.21)
0.97
(0.67-1.41)
0.84
(0.60-1.19)
0.93
(0.63-1.36)
 
ACrude (adjusted for age and sex)
BAdditionally adjusted for status of hormone replacement therapy (HRT), smoking status, alcohol, dietary fibre, red meat, physical activity and BMI.
C P-value for interaction for the adjusted estimates.

Discussion

Carriers of the del-allele of NFkB -94ins/del polymorphism were at statistically significantly higher risk of CRC than the homozygous carriers of the ins-allele.
Prospective studies have the advantage in relation to examining gene-environmental interactions that they are not encumbered by recall bias. In the present study, cases and cohort sample were selected from the same cohort, which together with complete follow up of the participants minimised the risk of selection bias. We have used the case-cohort study design in the present study. The case-cohort analysis is a more flexible design than a nested case-control design [49]. It permits us to use one large, randomly selected comparison group as comparison group for several nested studies within the Diet, Cancer and Health cohort, saving resources and valuable DNA, and the obtained risk estimates can be related directly to the cohort, which is population-based. We have previously used the same design in other studies of colorectal cancer [17, 19, 20, 39, 51], lung cancer [5255], and coronary heart disease [5659].
A main strength of our study is a well characterized study population. Information on lifestyle factors were collected at enrolment for all participants which minimised the risk of differential misclassification of cases and comparison group. However, lifestyle factors were only collected once, and may thus not be representative for the lifestyle during follow-up. This is, however, not expected to result in differential misclassification. Furthermore, information on food intake was based on a semi-quantitatively food frequency questionnaire [38, 44], which was evaluated and found usable [43]. The results were adjusted for known confounding factors affecting the risk of CRC in this cohort including dietary factors, body mass index (BMI), alcohol, smoking status, physical activity and NSAID use [1]. An additional strength of the present study is the high exposure of red and processed meat and tobacco smoke in the present study [3, 9]. Limitations of the study include the relatively small sample size. Therefore, heterozygous and homozygous variant genotype carriers were combined for the analyses of interactions to obtain sufficient statistical power. Nevertheless, in the light of the obtained P-values and the number of statistical testes performed, we cannot exclude that our positive findings may be due to chance.
We found a weak interaction between NFkB -94ins/del polymorphism and intake of red and processed meat in relation to CRC risk (Table 3). In the interaction analysis, we calculated the slopes of two curves describing the relationship between meat intake and CRC risk for homozygous carriers of the ins-allele and for carriers of the del-allele, respectively. However, either of the slopes is statistically significantly different from 1, as indicted by the confidence intervals. However, the two slopes were statistically significantly different from each other as indicated by the p-value for the interaction (p = 0.03). Furthermore, among homozygous carriers of the ins-allele of the NFkB -94ins/del polymorphism, risk of CRC was unchanged across tertiles of meat intake, whereas for del-allele carriers, the risk of CRC was higher for the second and the third tertile of meat intake compared to the first tertile (Table 4). In this analysis, there was no statistically significant interaction. Our study thus suggests that the NFkB polymorphism may be most important in study populations with high consumption of red and processed meat. The NFkB -94ins/del del-allele was associated with risk of CRC among Swedes, whereas no association was found among Chinese [32]. Hence, the difference between the findings in the Danish and Swedish on one hand and the Chinese on the other may be related to differences in meat exposure. Meat intake is much high in high income countries, including Denmark and Sweden, compared to low income countries, including China, respectively [3].
We have previously found interaction between meat intake and polymorphisms in the xenobiotic transporter MDR1 in relation to CRC in this study group [20]. Combined carriers of MDR1 intron 3 G-rs3789243A A-allele and NFkB -94ins/del del-allele have an IRR of 1.85 (95% confidence interval (CI): 1.15-3.00, p = 0.007) compared to the homozygous G-allele and ins-allele carriers, suggesting additive but no synergistic effect by having both risk alleles. However, the statistical power to explore gene-gene interactions was low. The two studies may suggest that a lower NFkB response by the NFkB del-allele carriers after stimulation by intestinal carcinogens may lead to a lower expression of the MDR1 [21] and, thus, a lower transport activity and, eventually, an impaired defence against intestinal uptake of luminal carcinogens compared to homozygous ins-allele carriers. Furthermore, interaction between meat and NFkB may be caused by a lower activation of NFkB del-allele relative to the ins-allele resulting in a high load of reactive oxygen species provided by heme degradation and which may contribute to carcinogenesis [60].
We found no interaction between the NFkB -94ins/del polymorphism and smoking status, suggesting that the carcinogen exposure from tobacco smoke, which comes from ingestion of inhaled tobacco smoke particles, is less than the carcinogen exposure from ingestion of red and processed meat. This is in accordance with our previous finding of smoking being a weaker risk factor for CRC than red and processed meat [20].
We found no statistically significant associations between the PXR and LXR polymorphisms and CRC risk, and no interaction with smoking status, use of NSAID, or intake of red and processed meat. These two genes have not previously been investigated in relation to CRC. We had from 73% to 99% chance to detect a dominant effect of the three studied polymorphisms in PXR using the ORs from the study of Dring [61] of 1.3-2.9 and similarly more than 84% chance of detecting a dominant effect with an OR of 1.5 in LXR. Our findings do therefore not support important roles of PXR and LXR in CRC etiology. This is in accordance with the observation that NFkB activation suppress the action of PXR and vice versa [62, 63].
We found no interaction between NSAID use and NFκB, PXR and LXR genotypes. A risk reducing affect of NSAID may be dependent on functional NFκB, as aspirin has been shown to induce apoptosis in intestinal cell lines by a NFκB dependent mechanism [64]. Long-term use of NSAID was associated with a protective effect against CRC in the "Diet, Cancer and Health" cohort, used in the present study [45]. Hence, the results do not support important roles of the studied genotypes in interaction with NSAID in CRC aetiology.

Conclusions

The present study indicated that the ins/del NFkB polymorphism may be involved in CRC etiologi. The ins/del NFkB polymorphism may affect the risk of CRC by exposure of meat as carriers of the NFkB del-allele were more susceptible to meat carcinogens than homozygous ins-allele carriers. This is the first study finding interaction between NFkB and meat intake in relation to CRC. However, the findings must be further evaluated in large populations with high meat intake.

Acknowledgements

Lars Bentzen is thanked for excellent technical assistance. We thank the staff at the Library, Viborg Regional Hospital. This work was supported by "Familien Erichsens Mindefond", The Lundbeck Foundation, "Johs M Klein og Hustrus mindelegat", "Agnete Løvgreens Legat", the Danish Cancer Society, grant DP00027, the grant ENGAGE from the Novo Nordisk Foundation and a grant from the Danish Ministry of Health, Research Centre for Environmental Health's Fund, ENGAGE.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

UV carried out the molecular genetic studies. UV, KO, AT participated in the design of the study and JC performed the statistical analysis. VA conceived the study and drafted the manuscript. All authors read and approved the final manuscript.
Anhänge

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.
Literatur
1.
Zurück zum Zitat Huxley RR, nsary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M: The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009, 125: 171-180. 10.1002/ijc.24343.CrossRefPubMed Huxley RR, nsary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M: The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009, 125: 171-180. 10.1002/ijc.24343.CrossRefPubMed
2.
Zurück zum Zitat Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009, 15: 425-430. 10.1158/1078-0432.CCR-08-0149.CrossRefPubMed Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009, 15: 425-430. 10.1158/1078-0432.CCR-08-0149.CrossRefPubMed
5.
Zurück zum Zitat Santarelli RL, Pierre F, Corpet DE: Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer. 2008, 60: 131-144. 10.1080/01635580701684872.CrossRefPubMedPubMedCentral Santarelli RL, Pierre F, Corpet DE: Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer. 2008, 60: 131-144. 10.1080/01635580701684872.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Oates PS, West AR: Heme in intestinal epithelial cell turnover, differentiation, detoxification, inflammation, carcinogenesis, absorption and motility. World J Gastroenterol. 2006, 12: 4281-4295.CrossRefPubMedPubMedCentral Oates PS, West AR: Heme in intestinal epithelial cell turnover, differentiation, detoxification, inflammation, carcinogenesis, absorption and motility. World J Gastroenterol. 2006, 12: 4281-4295.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Liang PS, Chen TY, Giovannucci E: Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009, 124: 2406-2415. 10.1002/ijc.24191.CrossRefPubMed Liang PS, Chen TY, Giovannucci E: Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009, 124: 2406-2415. 10.1002/ijc.24191.CrossRefPubMed
8.
Zurück zum Zitat Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ: Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol. 2009, 7: 682-688. 10.1016/j.cgh.2009.02.016.CrossRefPubMed Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ: Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol. 2009, 7: 682-688. 10.1016/j.cgh.2009.02.016.CrossRefPubMed
11.
Zurück zum Zitat Seitz M, Wirthmuller U, Moller B, Villiger PM: The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007, 46: 93-96. 10.1093/rheumatology/kel175.CrossRef Seitz M, Wirthmuller U, Moller B, Villiger PM: The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007, 46: 93-96. 10.1093/rheumatology/kel175.CrossRef
12.
Zurück zum Zitat Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007, 369: 1603-1613. 10.1016/S0140-6736(07)60747-8.CrossRefPubMed Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007, 369: 1603-1613. 10.1016/S0140-6736(07)60747-8.CrossRefPubMed
13.
Zurück zum Zitat Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, et al: Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: A Danish cohort study. Cancer Causes Control. 2009 Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, et al: Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: A Danish cohort study. Cancer Causes Control. 2009
14.
Zurück zum Zitat Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G: Aspirin, salicylates, and cancer. Lancet. 2009, 373: 1301-1309. 10.1016/S0140-6736(09)60243-9.CrossRefPubMed Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G: Aspirin, salicylates, and cancer. Lancet. 2009, 373: 1301-1309. 10.1016/S0140-6736(09)60243-9.CrossRefPubMed
15.
Zurück zum Zitat Stark LA, Din FV, Zwacka RM, Dunlop MG: Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001, 15: 1273-1275.PubMed Stark LA, Din FV, Zwacka RM, Dunlop MG: Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001, 15: 1273-1275.PubMed
16.
Zurück zum Zitat Goel A, Boland CR: Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol. 2009 Goel A, Boland CR: Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol. 2009
17.
Zurück zum Zitat Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, et al: Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res. 2007, 624: 88-100.CrossRefPubMed Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, et al: Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res. 2007, 624: 88-100.CrossRefPubMed
18.
Zurück zum Zitat Andersen V, Agerstjerne L, Jensen D, Ostergaard M, Saebo M, Hamfjord J, et al: The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med Genet. 2009, 10: 18-10.1186/1471-2350-10-18.CrossRefPubMedPubMedCentral Andersen V, Agerstjerne L, Jensen D, Ostergaard M, Saebo M, Hamfjord J, et al: The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med Genet. 2009, 10: 18-10.1186/1471-2350-10-18.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res. 2007, 619: 68-80.CrossRefPubMed Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res. 2007, 619: 68-80.CrossRefPubMed
20.
Zurück zum Zitat Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U: Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) gene and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009, 9: 407-10.1186/1471-2407-9-407.CrossRefPubMedPubMedCentral Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U: Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) gene and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009, 9: 407-10.1186/1471-2407-9-407.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Scotto KW: Transcriptional regulation of ABC drug transporters. Oncogene. 2003, 22: 7496-7511. 10.1038/sj.onc.1206950.CrossRefPubMed Scotto KW: Transcriptional regulation of ABC drug transporters. Oncogene. 2003, 22: 7496-7511. 10.1038/sj.onc.1206950.CrossRefPubMed
22.
Zurück zum Zitat Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, et al: Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics. 2008, 18: 439-448. 10.1097/FPC.0b013e3282f974dc.CrossRefPubMedPubMedCentral Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, et al: Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics. 2008, 18: 439-448. 10.1097/FPC.0b013e3282f974dc.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Teng S, Piquette-Miller M: Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol Pharm. 2008, 5: 67-76. 10.1021/mp700102q.CrossRefPubMed Teng S, Piquette-Miller M: Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol Pharm. 2008, 5: 67-76. 10.1021/mp700102q.CrossRefPubMed
24.
Zurück zum Zitat Chisaki I, Kobayashi M, Itagaki S, Hirano T, Iseki K: Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver. Biochim Biophys Acta. 2009, 1788: 2396-2403. 10.1016/j.bbamem.2009.08.014.CrossRefPubMed Chisaki I, Kobayashi M, Itagaki S, Hirano T, Iseki K: Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver. Biochim Biophys Acta. 2009, 1788: 2396-2403. 10.1016/j.bbamem.2009.08.014.CrossRefPubMed
25.
Zurück zum Zitat Wang D, DuBois RN: Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle. 2007, 6: 682-685.CrossRefPubMed Wang D, DuBois RN: Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle. 2007, 6: 682-685.CrossRefPubMed
26.
Zurück zum Zitat Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870.CrossRefPubMed Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870.CrossRefPubMed
27.
Zurück zum Zitat Kundu JK, Surh YJ: Inflammation: gearing the journey to cancer. Mutat Res. 2008, 659: 15-30. 10.1016/j.mrrev.2008.03.002.CrossRefPubMed Kundu JK, Surh YJ: Inflammation: gearing the journey to cancer. Mutat Res. 2008, 659: 15-30. 10.1016/j.mrrev.2008.03.002.CrossRefPubMed
28.
Zurück zum Zitat Sebban H, Courtois G: NF-kappaB and inflammation in genetic disease. Biochem Pharmacol. 2006, 72: 1153-1160. 10.1016/j.bcp.2006.08.006.CrossRefPubMed Sebban H, Courtois G: NF-kappaB and inflammation in genetic disease. Biochem Pharmacol. 2006, 72: 1153-1160. 10.1016/j.bcp.2006.08.006.CrossRefPubMed
29.
Zurück zum Zitat De Vry CG, Prasad S, Komuves L, Lorenzana C, Parham C, Le T, et al: Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut. 2007, 56: 524-533. 10.1136/gut.2006.096487.CrossRefPubMed De Vry CG, Prasad S, Komuves L, Lorenzana C, Parham C, Le T, et al: Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut. 2007, 56: 524-533. 10.1136/gut.2006.096487.CrossRefPubMed
30.
Zurück zum Zitat Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, et al: NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 2007, 130: 918-931. 10.1016/j.cell.2007.07.009.CrossRefPubMedPubMedCentral Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, et al: NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 2007, 130: 918-931. 10.1016/j.cell.2007.07.009.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, et al: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004, 13: 35-45. 10.1093/hmg/ddh008.CrossRefPubMed Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, et al: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004, 13: 35-45. 10.1093/hmg/ddh008.CrossRefPubMed
32.
Zurück zum Zitat Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, Arbman G, et al: Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol. 2007, 42: 1332-1338. 10.1080/00365520701396026.CrossRefPubMed Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, Arbman G, et al: Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol. 2007, 42: 1332-1338. 10.1080/00365520701396026.CrossRefPubMed
33.
Zurück zum Zitat di MA, Marinis ED, Ascenzi P, Marino M: Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med. 2009, 30: 297-343. 10.1016/j.mam.2009.04.002.CrossRef di MA, Marinis ED, Ascenzi P, Marino M: Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med. 2009, 30: 297-343. 10.1016/j.mam.2009.04.002.CrossRef
34.
Zurück zum Zitat Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, et al: Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest. 2006, 116: 2280-2289. 10.1172/JCI26283.CrossRefPubMedPubMedCentral Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, et al: Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest. 2006, 116: 2280-2289. 10.1172/JCI26283.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001, 11: 555-572. 10.1097/00008571-200110000-00003.CrossRefPubMed Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001, 11: 555-572. 10.1097/00008571-200110000-00003.CrossRefPubMed
36.
Zurück zum Zitat Rizzo G, Fiorucci S: PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol. 2006, 6: 421-427. 10.1016/j.coph.2006.03.012.CrossRefPubMed Rizzo G, Fiorucci S: PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol. 2006, 6: 421-427. 10.1016/j.coph.2006.03.012.CrossRefPubMed
37.
Zurück zum Zitat Infante J, Rodriguez-Rodriguez E, Mateo I, Llorca J, Vazquez-Higuera JL, Berciano J, et al: Gene-gene interaction between heme oxygenase-1 and liver X receptor-beta and Alzheimer's disease risk. Neurobiol Aging. 2008 Infante J, Rodriguez-Rodriguez E, Mateo I, Llorca J, Vazquez-Higuera JL, Berciano J, et al: Gene-gene interaction between heme oxygenase-1 and liver X receptor-beta and Alzheimer's disease risk. Neurobiol Aging. 2008
38.
Zurück zum Zitat Tjonneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, et al: Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health. 2007, 35: 432-441. 10.1080/14034940601047986.CrossRefPubMed Tjonneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, et al: Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health. 2007, 35: 432-441. 10.1080/14034940601047986.CrossRefPubMed
39.
Zurück zum Zitat Hansen R, Saebo M, Skjelbred CF, Nexo BA, Hagen PC, Bock G, et al: GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett. 2005, 229: 85-91. 10.1016/j.canlet.2005.04.019.CrossRefPubMed Hansen R, Saebo M, Skjelbred CF, Nexo BA, Hagen PC, Bock G, et al: GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett. 2005, 229: 85-91. 10.1016/j.canlet.2005.04.019.CrossRefPubMed
40.
Zurück zum Zitat Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer. 2008, 8: 54-10.1186/1471-2407-8-54.CrossRefPubMedPubMedCentral Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer. 2008, 8: 54-10.1186/1471-2407-8-54.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Prosky L, Asp NG, Furda I, DeVries JW, Schweizer TF, Harland BF: Determination of total dietary fiber in foods and food products: collaborative study. J Assoc Off Anal Chem. 1985, 68: 677-679.PubMed Prosky L, Asp NG, Furda I, DeVries JW, Schweizer TF, Harland BF: Determination of total dietary fiber in foods and food products: collaborative study. J Assoc Off Anal Chem. 1985, 68: 677-679.PubMed
43.
Zurück zum Zitat Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM: Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol. 1991, 20: 906-912. 10.1093/ije/20.4.906.CrossRefPubMed Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM: Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol. 1991, 20: 906-912. 10.1093/ije/20.4.906.CrossRefPubMed
44.
Zurück zum Zitat Tjonneland A, Haraldsdottir J, Overvad K, Stripp C, Ewertz M, Jensen OM: Influence of individually estimated portion size data on the validity of a semiquantitative food frequency questionnaire. Int J Epidemiol. 1992, 21: 770-777. 10.1093/ije/21.4.770.CrossRefPubMed Tjonneland A, Haraldsdottir J, Overvad K, Stripp C, Ewertz M, Jensen OM: Influence of individually estimated portion size data on the validity of a semiquantitative food frequency questionnaire. Int J Epidemiol. 1992, 21: 770-777. 10.1093/ije/21.4.770.CrossRefPubMed
45.
Zurück zum Zitat Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, et al: Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control. 2009, 20: 731-740. 10.1007/s10552-008-9286-7.CrossRefPubMed Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, et al: Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control. 2009, 20: 731-740. 10.1007/s10552-008-9286-7.CrossRefPubMed
46.
Zurück zum Zitat Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, et al: Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res. 2007, 624: 88-100.CrossRefPubMed Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, et al: Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res. 2007, 624: 88-100.CrossRefPubMed
47.
Zurück zum Zitat Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-10.1093/nar/16.3.1215.CrossRefPubMedPubMedCentral Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-10.1093/nar/16.3.1215.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, et al: The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2009, 43: 539-545. 10.1038/bmt.2008.351.CrossRefPubMed Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, et al: The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2009, 43: 539-545. 10.1038/bmt.2008.351.CrossRefPubMed
49.
Zurück zum Zitat Barlow WE, Ichikawa L, Rosner D, Izumi S: Analysis of case-cohort designs. J Clin Epidemiol. 1999, 52: 1165-1172. 10.1016/S0895-4356(99)00102-X.CrossRefPubMed Barlow WE, Ichikawa L, Rosner D, Izumi S: Analysis of case-cohort designs. J Clin Epidemiol. 1999, 52: 1165-1172. 10.1016/S0895-4356(99)00102-X.CrossRefPubMed
50.
Zurück zum Zitat Barlow WE: Robust variance estimation for the case-cohort design. Biometrics. 1994, 50: 1064-1072. 10.2307/2533444.CrossRefPubMed Barlow WE: Robust variance estimation for the case-cohort design. Biometrics. 1994, 50: 1064-1072. 10.2307/2533444.CrossRefPubMed
51.
Zurück zum Zitat Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer. 2008, 8: 54-10.1186/1471-2407-8-54.CrossRefPubMedPubMedCentral Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer. 2008, 8: 54-10.1186/1471-2407-8-54.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Raaschou-Nielsen O, Sorensen M, Overvad K, Tjonneland A, Vogel U: Polymorphisms in nucleotide excision repair genes, smoking and intake of fruit and vegetables in relation to lung cancer. Lung Cancer. 2007 Raaschou-Nielsen O, Sorensen M, Overvad K, Tjonneland A, Vogel U: Polymorphisms in nucleotide excision repair genes, smoking and intake of fruit and vegetables in relation to lung cancer. Lung Cancer. 2007
53.
Zurück zum Zitat Raaschou-Nielsen O, Sorensen M, Hansen RD, Frederiksen K, Tjonneland A, Overvad K, et al: GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer. Cancer Lett. 2007, 247: 293-300. 10.1016/j.canlet.2006.05.006.CrossRefPubMed Raaschou-Nielsen O, Sorensen M, Hansen RD, Frederiksen K, Tjonneland A, Overvad K, et al: GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer. Cancer Lett. 2007, 247: 293-300. 10.1016/j.canlet.2006.05.006.CrossRefPubMed
54.
Zurück zum Zitat Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, et al: Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008, 639: 89-100.CrossRefPubMed Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, et al: Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008, 639: 89-100.CrossRefPubMed
55.
Zurück zum Zitat Sorensen M, Raaschou-Nielsen O, Hansen RD, Tjonneland A, Overvad K, Vogel U: Interactions between the OGG1 Ser326Cys polymorphism and intake of fruit and vegetables in relation to lung cancer. Free Radic Res. 2006, 40: 885-891. 10.1080/10715760600733129.CrossRefPubMed Sorensen M, Raaschou-Nielsen O, Hansen RD, Tjonneland A, Overvad K, Vogel U: Interactions between the OGG1 Ser326Cys polymorphism and intake of fruit and vegetables in relation to lung cancer. Free Radic Res. 2006, 40: 885-891. 10.1080/10715760600733129.CrossRefPubMed
56.
Zurück zum Zitat Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, et al: Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis. 2010, 209: 155-162. 10.1016/j.atherosclerosis.2009.08.036.CrossRefPubMed Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, et al: Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis. 2010, 209: 155-162. 10.1016/j.atherosclerosis.2009.08.036.CrossRefPubMed
57.
Zurück zum Zitat Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, et al: PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes. BMC Med Genet. 2009, 10: 52-10.1186/1471-2350-10-52.CrossRefPubMedPubMedCentral Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, et al: PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes. BMC Med Genet. 2009, 10: 52-10.1186/1471-2350-10-52.CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Jensen MK, Rimm EB, Mukamal KJ, Edmondson AC, Rader DJ, Vogel U, et al: The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J. 2009, 30: 1584-1589. 10.1093/eurheartj/ehp145.CrossRefPubMedPubMedCentral Jensen MK, Rimm EB, Mukamal KJ, Edmondson AC, Rader DJ, Vogel U, et al: The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J. 2009, 30: 1584-1589. 10.1093/eurheartj/ehp145.CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Jensen MK, Rimm EB, Rader D, Schmidt EB, Sorensen TI, Vogel U, et al: S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies. Am Heart J. 2009, 157: 384-390. 10.1016/j.ahj.2008.10.008.CrossRefPubMedPubMedCentral Jensen MK, Rimm EB, Rader D, Schmidt EB, Sorensen TI, Vogel U, et al: S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies. Am Heart J. 2009, 157: 384-390. 10.1016/j.ahj.2008.10.008.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Legrand-Poels S, Zecchinon L, Piret B, Schoonbroodt S, Piette J: Involvement of different transduction pathways in NF-kappa B activation by several inducers. Free Radic Res. 1997, 27: 301-309. 10.3109/10715769709065768.CrossRefPubMed Legrand-Poels S, Zecchinon L, Piret B, Schoonbroodt S, Piette J: Involvement of different transduction pathways in NF-kappa B activation by several inducers. Free Radic Res. 1997, 27: 301-309. 10.3109/10715769709065768.CrossRefPubMed
61.
Zurück zum Zitat Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, et al: The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006, 130: 341-348. 10.1053/j.gastro.2005.12.008.CrossRefPubMed Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, et al: The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006, 130: 341-348. 10.1053/j.gastro.2005.12.008.CrossRefPubMed
62.
Zurück zum Zitat Aitken AE, Richardson TA, Morgan ET: Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006, 46: 123-149. 10.1146/annurev.pharmtox.46.120604.141059.CrossRefPubMed Aitken AE, Richardson TA, Morgan ET: Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006, 46: 123-149. 10.1146/annurev.pharmtox.46.120604.141059.CrossRefPubMed
63.
Zurück zum Zitat Wang K, Wan YJ: Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood). 2008, 233: 496-506. 10.3181/0708-MR-231.CrossRef Wang K, Wan YJ: Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood). 2008, 233: 496-506. 10.3181/0708-MR-231.CrossRef
64.
Zurück zum Zitat Din FV, Dunlop MG, Stark LA: Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer. 2004, 91: 381-388.PubMedPubMedCentral Din FV, Dunlop MG, Stark LA: Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer. 2004, 91: 381-388.PubMedPubMedCentral
Metadaten
Titel
Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes
verfasst von
Vibeke Andersen
Jane Christensen
Kim Overvad
Anne Tjønneland
Ulla Vogel
Publikationsdatum
01.12.2010
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2010
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-484

Weitere Artikel der Ausgabe 1/2010

BMC Cancer 1/2010 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.